The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors

The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors

Background and aimSarcopenia has gained considerable attention in the context of hepatocellular carcinoma, as it has been correlated with a poorer prognosis among patients undergoing sorafenib or lenvatinib treatment for hepatocellular carcinoma (HCC). The clinical significance of sarcopenia in firs...

Full description

Bibliographic Details
Main Authors:	Wei Sun, Xue Yin, Xiaomin Liu, Jianying Wei, Minghua Yu, Wendong Li, Xiaoyan Ding, Jinglong Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Immunology
Subjects:	sarcopenia HCC PD-1 inhibitor lenvatinib psoas muscle index
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1380477/full

Similar Items

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study
by: Xu Chang, et al.
Published: (2024-04-01)

Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
by: Katsuya Toshida, et al.
Published: (2022-07-01)

The role of sarcopenia in fragility fractures of the pelvis – is sarcopenia an underestimated risk factor?
by: Olivia Mair, et al.
Published: (2024-05-01)

Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis
by: Dae Hoe Gu, et al.
Published: (2018-09-01)

Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial
by: Guangxin Li, et al.
Published: (2022-11-01)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
by: Jie Zhu, et al.
Published: (2021-11-01)

Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression
by: Peng Sun, et al.
Published: (2024-07-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
by: Yongkang Xu, et al.
Published: (2022-09-01)

Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
by: Peng Guo, et al.
Published: (2022-10-01)

Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with Extrahepatic Metastasis
by: Duan WB, et al.
Published: (2024-05-01)

The Prognostic Value of Peripheral Blood Inflammatory Markers in Hepatocellular Carcinoma Treated with Lenvatinib Combined with PD-1 Inhibitors
by: Xin Y, et al.
Published: (2025-01-01)

The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study
by: Zongren Ding, et al.
Published: (2024-06-01)

Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis
by: Lingling Zhao, et al.
Published: (2025-02-01)

Prognostic Value of Sarcopenia in Elderly Patients with Metastatic Non-Small-Cell Lung Cancer Undergoing Radiotherapy
by: Valerio Nardone, et al.
Published: (2024-10-01)

Sarcopenia in Children with Solid Organ Tumors: An Instrumental Era
by: Annika Ritz, et al.
Published: (2022-04-01)

Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study
by: Wei F, et al.
Published: (2021-05-01)

Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit
by: Zhangbin Chen, et al.
Published: (2022-03-01)

Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis
by: Xu K, et al.
Published: (2024-06-01)

Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
by: JIANG Jiayun, et al.
Published: (2024-11-01)

Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
by: Yang H, et al.
Published: (2023-09-01)

Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization
by: Shi Q, et al.
Published: (2023-10-01)

Assessment of Psoas Muscle Index in Middle-Aged Type 2 Diabetes Patients: Impact of Insulin Therapy on Sarcopenia
by: Ismail Taskent, et al.
Published: (2024-07-01)

Psoas muscle quantified muscle status and long-term mortality after cardiovascular interventions
by: Otto Järvinen, et al.
Published: (2023-12-01)

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
by: Jia M, et al.
Published: (2022-09-01)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023-10-01)

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS
by: Jun Guo, et al.
Published: (2021-10-01)

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
by: Chang X, et al.
Published: (2023-06-01)

Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications
by: Xuqi Sun, et al.
Published: (2022-03-01)

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01)

Sintilimab Combined with Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma in Second-Line Setting—A Multi-Center Observational Study
by: Xiaoyan Ding, et al.
Published: (2022-07-01)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
by: Ronen Stoff, et al.
Published: (2023-05-01)

PD-1 inhibitor combined with chemotherapy or lenvatinib in advanced gallbladder cancer: a retrospective comparative study
by: Hong-yan Ma, et al.
Published: (2025-02-01)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
by: Wei‐Jun Wang, et al.
Published: (2023-05-01)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
by: Graziana Digiacomo, et al.
Published: (2022-07-01)

The Impact of Sarcopenia in the Long-Term Survival of Patients following Complex Endovascular Aortic Surgery for Thoracoabdominal Aortic Aneurysms
by: Georgios Sachsamanis, et al.
Published: (2024-04-01)

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)

Total Psoas Muscle Area as a Marker for Sarcopenia Is Related to Outcome in Children With Neuroblastoma
by: Annika Ritz, et al.
Published: (2021-08-01)

The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects
by: Hirotetsu Takagi, et al.
Published: (2021-03-01)

Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
by: Lulu Xie, et al.
Published: (2022-06-01)